Literature DB >> 23739700

Lymphangiectatic Kaposi's sarcoma in a patient with AIDS.

Mônica Santos1, Virginia Vilasboas, Luciana Mendes, Carolina Talhari, Sinésio Talhari.   

Abstract

Kaposi's sarcoma is a malignant disease that originates in the lymphatic endothelium. It has a broad spectrum of clinical manifestations. Its four distinct clinical forms are: classic, endemic, iatrogenic and epidemic Kaposi's sarcoma. In non-HIV-associated Kaposi's sarcoma, the disease is typically limited to the lower extremities, but in immunodeficient patients, it is a multifocal systemic disease. The clinical course of the disease differs among patients, ranging from a single or a few indolent lesions to an aggressive diffuse disease. Advanced Kaposi's sarcoma lesions, typically those on the lower extremities, are often associated with lymphedema. In this paper, we report a case of a patient with a rare form of AIDS-associated Kaposi sarcoma called lymphangiectatic Kaposis's sarcoma.

Entities:  

Mesh:

Year:  2013        PMID: 23739700      PMCID: PMC3750897          DOI: 10.1590/S0365-05962013000200019

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


INTRODUCTION

Kaposi's sarcoma (KS) is a neoplasm that originates in the lymphatic endothelium and has a broad spectrum of clinical manifestations. [1] There are four distinct clinical forms of the disease: classic KS, endemic, iatrogenic and epidemic or HIV-associated. The etiological agent of all forms of Kaposi's sarcoma is the human herpesvirus 8 (HHV8), also known as Kaposi's sarcoma-associated herpesvirus (KSHV). [2] In classic KS, the disease is typically limited to the lower extremities, although it may be more widespread. In immunodeficient patients, such as patients with AIDS or those who have undergone a solid organ transplant, KS is a multifocal systemic disease. All clinical forms may present with lymphedema due to blockage of lymph vessels, changes in the permeability of the lymphatics, regional lymph node involvement and increased inflammatory cytokines. However, this clinical manifestation is more frequent in classic KS.[3] Most skin lesions show a typical histological picture, but several histological variants, including lymphangiectatic KS, have recently been described. [4] We report the case of a patient with a rare form of Aids-associated KS, without visceral involvement, presenting with an unusual clinical and histopathological picture called AIDS-associated lymphangiectatic KS.

CASE REPORT

In 2001, a 32-year-old male was referred to the department of dermatology reporting a history of lesions in the proximal right thigh. A skin biopsy was performed and suggested diagnosis of KS. A partial improvement was noted when antiretroviral therapy (TARV) was started, but the patient was lost to follow-up. At diagnosis, CD4+ T-cell count was 409 cells/mm3 and viral load 76,000 copies/mm[3]. In 2010, the patient returned with a worsening clinical status, including an increased number of lesions and edema around the right lower limb. Dermatological examination revealed isolated and confluent erythematousviolaceous tuberous lesions of varying sizes as well as a vegetating tumor on the inner right thigh (Figures 1 and 2). Histopathological examination revealed inter-cellular epidermal edema, proliferation of spindle cells, neoangiogenesis and large dilated intratumoral and peritumoral thin-walled lymphatic vessels (Figure 3). Magnetic resonance imaging showed a volumetric increase in the diameter of the entire right thigh associated with severe edema of the entire subcutaneous tissue and a heterogeneous, hypodense area in the proximal right thigh (Figure 4). Lymphangiocintigraphy revealed bilateral retention of the radiotracer, which was more pronounced in the right lower limb, with signs of lymphatic leakage (Figure 5). CT scan of the skull and chest showed no abnormalities and the endoscopy was normal. The patient was referred to a specialized cancer treatment center, where he resumed chemotherapy with paclitaxel, with partial reduction of edema and lesions.
FIGURE 1

Isolated and confluent erythematous-violaceous tuberous lesions of varying sizes with substantial edema formation in the right leg

FIGURE 2

Isolated and confluent erythematous-violaceous tuberous lesions of varying sizes, and a vegetating tumor on the inner right thigh

FIGURE 3

Intercellular epidermal edema, proliferation of spindle cells, neoangiogenesis and there are large dilated intratumoral and peritumoral thin-walled lymphatic vessels

FIGURE 4

Magnetic resonance imaging showed a volumetric increase in the diameter of the entire right thigh associated with severe edema of the entire subcutaneous tissue and a heterogeneous, hypodense area in the proximal right thigh

FIGURE 5

Lymphangioscintigraphy revealed bilateral retention of the radiotracer, which was more pronounced in the right lower limb, with signs of lymphatic leakage

Isolated and confluent erythematous-violaceous tuberous lesions of varying sizes with substantial edema formation in the right leg Isolated and confluent erythematous-violaceous tuberous lesions of varying sizes, and a vegetating tumor on the inner right thigh Intercellular epidermal edema, proliferation of spindle cells, neoangiogenesis and there are large dilated intratumoral and peritumoral thin-walled lymphatic vessels Magnetic resonance imaging showed a volumetric increase in the diameter of the entire right thigh associated with severe edema of the entire subcutaneous tissue and a heterogeneous, hypodense area in the proximal right thigh Lymphangioscintigraphy revealed bilateral retention of the radiotracer, which was more pronounced in the right lower limb, with signs of lymphatic leakage

DISCUSSION

AIDS-associated KS is a tumour of lymphatic endothelial origin that affects mucocutanous sites, but may also involve internal organs. The condition usually appears first as pink, purple, red or brown/black nodules or patches on the skin or mucosa. [5] The clinical course of the disease differs among patients, ranging from a single or a few indolent lesions to an aggressive diffuse disease that can rapidly cause severe complications. [6] Extensive AIDS-associated KS lesions, typically those on the lower extremities, are often associated with lymphedema. In this setting, lymphedema may be due to lymphatic obstruction, altered lymphatic drainage, leakage from dilated lymphatics or regional lymph node involvement. In addition to the factors mentioned previously, the development of lymphedema in KS lesions may be attributed to the HHV-8-induced exuberant proliferation of endothelial cells that may lead to the occlusion of lymphatic lumens.[7] Clinical and histological lymphedematous variants of AIDS-associated KS have been described more recently. These include variants associated with ectatic lymphatics (as lymphangioma-like and lymphangiectatic KS), and variants with subepidermal and intraepidermal edema (as bullous KS). Lymphangiectatic and lymphangioma-like KS are associated with ectatic lymphatics. However, in lymphangiectatic KS there were large dilated intratumoral and peritumoral thin-walled lymphatic vessels. [8] In HIV-infected patients, KS is one of the indications for starting TARV. TARV has significantly changed the morbidity and mortality associated with KS and has also reduced its incidence.[9] Local treatment modalities (intralesional vinblastine, cryotherapy, laser and radiation) are useful if skin or mucosal lesions are few and there is no systemic involvement. Indications for systemic treatment of KS are visceral involvement, extensive KS-associated lymphedema, extensive and rapidly progressive cutaneous KS and failure to respond to local treatment. Anthracyclines (doxorubicin and daunorubicin) and paclitaxel are agents used to treat KS. Other systemic treatment modalities include inter-feron-alpha and combination chemotherapies with adriamycin, bleomycin plus vincristine or vinblastine. [10] In this paper we report a case of Aids-associated KS, without visceral involvement, with intense lymphatic impairment and a rare histological variant.
  9 in total

Review 1.  Kaposi's sarcoma.

Authors:  K Antman; Y Chang
Journal:  N Engl J Med       Date:  2000-04-06       Impact factor: 91.245

Review 2.  Lymphangioma-like Kaposi's sarcoma: report of four cases and review.

Authors:  S Mohanna; J Sanchez; J C Ferrufino; F Bravo; E Gotuzzo
Journal:  J Eur Acad Dermatol Venereol       Date:  2006-09       Impact factor: 6.166

Review 3.  Lymphangioma-like Kaposi's sarcoma: etiology and literature review.

Authors:  D A Davis; D M Scott
Journal:  J Am Acad Dermatol       Date:  2000-07       Impact factor: 11.527

Review 4.  Kaposi's sarcoma: an update.

Authors:  Robert A Schwartz
Journal:  J Surg Oncol       Date:  2004-09-01       Impact factor: 3.454

Review 5.  The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome.

Authors:  B Safai; K G Johnson; P L Myskowski; B Koziner; S Y Yang; S Cunningham-Rundles; J H Godbold; B Dupont
Journal:  Ann Intern Med       Date:  1985-11       Impact factor: 25.391

6.  Kaposi's sarcoma in an HIV-positive person successfully treated with paclitaxel.

Authors:  Atul Dongre; Chiara Montaldo
Journal:  Indian J Dermatol Venereol Leprol       Date:  2009 May-Jun       Impact factor: 2.545

7.  Human Herpesvirus 8 (HHV8) sequentially shapes the NK cell repertoire during the course of asymptomatic infection and Kaposi sarcoma.

Authors:  Stéphanie Dupuy; Marion Lambert; David Zucman; Siméon-Pierre Choukem; Sara Tognarelli; Cécile Pages; Céleste Lebbé; Sophie Caillat-Zucman
Journal:  PLoS Pathog       Date:  2012-01-12       Impact factor: 6.823

8.  Histological variants of cutaneous Kaposi sarcoma.

Authors:  Wayne Grayson; Liron Pantanowitz
Journal:  Diagn Pathol       Date:  2008-07-25       Impact factor: 2.644

9.  The prognostic significance of facial lymphoedema in HIV-seropositive subjects with Kaposi sarcoma.

Authors:  L Feller; Jn Masipa; Nh Wood; Ej Raubenheimer; J Lemmer
Journal:  AIDS Res Ther       Date:  2008-01-29       Impact factor: 2.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.